President Donald Trump’s proposed 2018 budget doesn’t spare Seattle-area biotechnology companies, which have remained cautiously optimistic that the new administration would go easy on the industry after a rollercoaster election season that sent stock prices tumbling.
The budget “blueprint” would sharply increase user fees that the Food and Drug Administration charges drug companies and medical-device makers to review their products, more than doubling current user fees to $2 billion a year.
FDA…
President Donald Trump’s proposed 2018 budget doesn’t spare Seattle-area biotechnology companies, which have remained cautiously optimistic that the new administration would go easy on the industry after a rollercoaster election season that sent stock prices tumbling.
The budget “blueprint” would sharply increase user fees that the Food and Drug Administration charges drug companies and medical-device makers to review their products, more than doubling current user fees to $2 billion a year.
FDA…